For localized information and support, would you like to switch to your country-specific website for {0}?
Anticoagulation: From today to the future
playicon
videoCtrl
/
fullScreen
Update Required
To play the media you will need to either update your browser to a recent version or update your
Flash plugin.
In the words of Dr. Melchior Nierman, we’re living in an epidemic of bad lifestyles. In this landscape of rising illness, our approach to thrombosis and the prevention of strokes need our attention.
We’re thrilled that for 2024’s first ASPIRE webinar, we welcomed thrombosis expert Dr. Nierman to share his perspective of the present and future of thrombosis management.
Dr. Nierman begins this webinar with an introduction to thrombosis and the different lines of available treatment, before diving into vitamin K antagonists (VKAs). He first explores how they work, their therapeutic ranges, the importance of monitoring INR, and factors that impact efficacy. Then he compares VKAs to the most popular treatment for atrial fibrillation and venous thrombosis: DOACs.
The real value of this webinar comes through Dr. Nierman’s presentation of the FRAIL-AF study that he was pivotal in conducting. His findings about the safety of switching elderly patients away from VKAs in the Netherlands and the implications for the future of thrombosis care are truly insightful.
This lunch break-friendly webinar will surely enrich your understanding of Anticoagulation Management, and we hope you enjoy.
The views and opinions expressed in this webinar are those of the speakers and do not necessarily reflect the views or positions of Roche or any other sponsor